$8.22
0.72% day before yesterday
Nasdaq, Jun 28, 10:19 pm CET
ISIN
US89422G1076
Symbol
TVTX
Sector
Industry

Travere Therapeutics Inc Share price

$8.22
+1.46 21.60% 1M
-1.19 12.65% 6M
-0.77 8.57% YTD
-7.36 47.24% 1Y
-7.26 46.90% 3Y
-11.87 59.08% 5Y
-3.52 29.98% 10Y
Nasdaq, Closing price Fri, Jun 28 2024
ISIN
US89422G1076
Symbol
TVTX
Sector
Industry

Key figures

Market capitalization $625.78m
Enterprise Value $588.76m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.21
P/S ratio (TTM) P/S ratio 3.42
P/B ratio (TTM) P/B ratio 8.45
Sales growth (TTM) Sales growth -16.91%
Turnover (TTM) Turnover $183.23m
EBIT (operating result TTM) EBIT $-334.94m
Free cash flow (TTM) Free cash flow $-317.95m
Cash position $441.04m
EPS (TTM) EPS $-5.06
P/E ratio expected negative
P/S ratio expected 2.91
EV/Sales expected 2.74
Short interest 19.83%
Show more

Is Travere Therapeutics Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Travere Therapeutics Inc Share analysis

Unlock scores for free

Analyst opinions

16 Analysts have issued a Travere Therapeutics Inc forecast:

11x Buy
69%
5x Hold
31%

Analyst opinions

16 Analysts have issued a Travere Therapeutics Inc forecast:

Buy
69%
Hold
31%

Financial data from Travere Therapeutics Inc

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
183 183
17% 17%
100%
- Direct costs 56 56
22% 22%
31%
127 127
27% 27%
69%
- Selling and administrative expenses 181 181
1% 1%
99%
- Research and development costs 233 233
1% 1%
127%
-288 -288
20% 20%
-157%
- Depreciation and amortization 47 47
33% 33%
26%
EBIT (operating result) EBIT -335 -335
22% 22%
-183%
Net profit -387 -387
34% 34%
-211%

Figures in millions USD.

Don't miss a thing! We will send you all news about the Travere Therapeutics Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Travere Therapeutics Inc Share News

Neutral
GlobeNewsWire
18 days ago
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 10,500 shares of its common stock. These inducement RSUs are subject to the t...
Neutral
GlobeNewsWire
about 2 months ago
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) --  Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 51,500 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and ind...
Neutral
GlobeNewsWire
about 2 months ago
Presentations highlight data supporting FILSPARI ® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN
More Travere Therapeutics Inc News

Company profile

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Eric Dube
Employees 380
Founded 2008
Website www.travere.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now